Discussion Reloxin-Impact on Botulinium Toxin A Market_MAY2006
May 2006
Deliverable: Transcripts Only

Objectives:

• Better understand market for botulinum toxin type A
• Elicit opinions on a new botulinum toxin type A product (Reloxin) currently marketed outside the US as Dysport
• Understand how Reloxin will impact the use of Botox and alter the US marketplace

Products Highlighted:

• Botox (Allergan)
• Reloxin (Medicis)

Topics:

• Current use of botulinum toxin type A
• Impressions of Reloxin / Dysport
• Impact of conversion rate ambiguity for Botox to Reloxin
• Comparison of mixing Reloxin to that of other therapies
• Diffusion and duration expectations of Reloxin
• Patient satisfaction with Botox and Reloxin
• Drivers of switch from Botox to Reloxin
• Effective marketing strategies

Quotes:

• “I primarily use botulinum toxin for the treatment of…”
• “The rumors that it diffuses farther from the muscle…”
• “Factors that may drive Reloxin use are…”
• “If I tell them (patients) I have a safe “generic” competitor…”

Screening Criteria:

• Cosmetic Dermatologists and Dermatologic Surgeons (n=6)
• Board certified
• Familiar with both botulinum toxin type A products
• Some panelists experienced in using Reloxin/ Dysport
• Performing 40 injections of botulinum toxin type A per month

Representative Institutions:

• Boston Dermatology
• University of Pennsylvania
• St. Vincents
• Beth Israel
• Longevity Institute